NCT06249750 Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer
| NCT ID | NCT06249750 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Pengyuan Liu |
| Condition | Metastatic Castration-resistant Prostate Cancer (CRPC) |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-01-01 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 60 participants in total. It began in 2024-01-01 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In this study, we propose to use the combination of ET-SPACE NIR irradiation whole-body thermal stimulation, ICI (Tislelizumab), and RTK inhibitor (Anlotinib) in the multimodal treatment of CRPC.
Eligibility Criteria
Inclusion Criteria: * Histopathologically confirmed diagnosis of PC and clinically confirmed diagnosis of CRPC; * Complete and reliable medical history and medical records; * No other primary tumors except CRPC; * Blood tests, liver function, renal function and electrocardiogram are basically normal; * Patients with ECOG score 0\~3, aged ≥18 years and \<90 years old; * Patients with good compliance, able to accept regular follow-up. Exclusion Criteria: * History of malignant tumor other than PC within the past 5 years; * Severe abnormalities in the patient's laboratory indices may jeopardize patient safety or compromise this study; * Accompanied by severe underlying diseases that cannot tolerate this therapy; * With acute diseases, such as acute infection, active bleeding; * Those who have recently participated in other clinical trials and have not passed the washout period; * Those who cannot tolerate systemic heat stress, such as claustrophobic patients; * Those who have a history of allergy to the drugs used in the trial; * Patients with other reasons for not being able to be enrolled in the study, according to the study doctor.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06249750 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 90 Years, studying Metastatic Castration-resistant Prostate Cancer (CRPC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06249750 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06249750 currently recruiting?
Yes, NCT06249750 is actively recruiting participants. Contact the research team at oncologyliupengyuan@outlook.com for enrollment information.
Where is the NCT06249750 trial being conducted?
This trial is being conducted at Hangzhou, China.
Who is sponsoring the NCT06249750 clinical trial?
NCT06249750 is sponsored by Pengyuan Liu. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.